A Double-Blind, Controlled Phase 2b Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Ischemic Stroke

Trial Profile

A Double-Blind, Controlled Phase 2b Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Ischemic Stroke

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs SB 623 (Primary)
  • Indications Stroke
  • Focus Therapeutic Use
  • Acronyms ACTISSIMA
  • Sponsors SanBio
  • Most Recent Events

    • 16 Oct 2017 Status changed from recruiting to active, no longer recruiting.
    • 05 Jul 2017 According to a SanBio Inc. media release, enrollment in this trial is expected to be complete in March 2018 and results are expected in 2019.
    • 05 Jul 2017 According to a SanBio Inc. media release, the California Institute of Regenerative Medicine (CIRM) has awarded a $20 million grant in support of this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top